Related Experiment Video
Updated: Apr 27, 2026
Comparative Strategies for Ubiquitination Detection in Mammalian Cell Lysates Using SMAD2/SMURF2 as a Model
Published on: April 17, 2026
Lysine methyltransferase Smyd2 suppresses p53-dependent cardiomyocyte apoptosis
Amna Sajjad1, Tatyana Novoyatleva2, Silvia Vergarajauregui3
1Department of Cardiac Development and Remodelling, Max-Planck-Institute for Heart and Lung Research, Parkstrasse 1, 61231 Bad Nauheim, Germany; Govt. College University Faisalabad, Allama Iqbal Road, Faisalabad 38000, Punjab, Pakistan.
Abstract:
Apoptosis, or programmed cell death, is an essential physiological process for proper embryogenesis as well as for homeostasis during aging. In addition, apoptosis is one of the major mechanisms causing cell loss in pathophysiological conditions such as heart failure. Thus, inhibition of apoptosis is an important approach for preventive and therapeutic strategies. Here we show that the histone 3 lysine 4- and lysine 36-specific methyltransferase Smyd2 acts as an endogenous antagonistic player of p53-dependent cardiomyocyte apoptosis. Smyd2 protein levels were significantly decreased in cardiomyocytes upon cobalt chloride-induced apoptosis or myocardial infarction, while p53 expression was enhanced. siRNA-mediated knockdown of Smyd2 in cultured cardiomyocytes further enhanced cobalt chloride-induced cardiomyocyte apoptosis. In contrast, Smyd2 overexpression resulted in marked methylation of p53 and prevented its accumulation as well as apoptotic cell death in an Hsp90-independent manner. Moreover, overexpression, of Smyd2, but not Smyd2Y240F lacking a methyl transferase activity, significantly rescued CoCl2-induced apoptosis in H9c2 cardioblasts. Finally, Smyd2 cardiomyocyte-specific deletion in vivo promoted apoptotic cell death upon myocardial infarction, which correlated with enhanced expression of p53 and pro-apoptotic Bax. Collectively, our data indicate Smyd2 as a cardioprotective protein by methylating p53.
Insights
Smyd2 protein protects heart cells from programmed cell death (apoptosis) by modifying p53. Reduced Smyd2 levels increase heart cell death, highlighting Smyd2
Area of Science:
- Cardiovascular Biology
- Molecular Biology
- Cell Death Research
Background:
- Apoptosis, or programmed cell death, is crucial for development and homeostasis but contributes to heart failure.
- Inhibiting apoptosis is a key therapeutic strategy for cardiovascular diseases.
Purpose of the Study:
- To investigate the role of Smyd2 in cardiomyocyte apoptosis and its potential as a therapeutic target.
- To elucidate the mechanism by which Smyd2 regulates p53-dependent apoptosis in heart cells.
Main Methods:
- Utilized siRNA-mediated knockdown and overexpression of Smyd2 in cultured cardiomyocytes and H9c2 cardioblasts.
- Assessed apoptosis via cell death assays and measured protein levels of Smyd2 and p53.
- Investigated the methyltransferase activity of Smyd2 using a mutant form (Smyd2Y240F).
- Conducted in vivo studies with cardiomyocyte-specific Smyd2 deletion in a myocardial infarction model.
Main Results:
- Smyd2 protein levels decreased, while p53 expression increased during induced apoptosis and myocardial infarction.
- Smyd2 knockdown exacerbated cardiomyocyte apoptosis; Smyd2 overexpression inhibited it.
- Smyd2 directly methylated p53, preventing its accumulation and subsequent apoptosis independently of Hsp90.
- Smyd2's methyltransferase activity was essential for its protective function.
- In vivo Smyd2 deletion worsened heart damage and increased apoptosis after myocardial infarction.
Conclusions:
- Smyd2 acts as an endogenous protective factor against cardiomyocyte apoptosis.
- Smyd2 exerts its cardioprotective effects by methylating and inhibiting p53.
- Targeting Smyd2 may offer a novel therapeutic approach for preventing heart failure.
Related Concept Videos
02:23Abnormal Proliferation
01:31The Intrinsic Apoptotic Pathway